Research and Markets: China Human Vaccine Industry Report, 2012-2015

Business Wire

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/jl9tz5/china_human) has announced the addition of the "China Human Vaccine Industry Report, 2012-2015" report to their offering.

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market.

However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each.

In recent years, China has made some achievements in overseas vaccine markets. In 2011-2012, China's annual human vaccine export volume remained over 9,000 tons (9,840 tons in 2010 was subject to the accidental H1N1 flu event), far more than 8,110 tons in 2009. Moreover, many domestic vaccine companies are still planning overseas markets aggressively.

Key Topics Covered

1. Overview of Vaccine Industry

1.1 Definition & Classification

1.2 Industry Chain

2. Overview of China Human Vaccine Industry

2.1 Overview

2.2 Operating Environment

2.3 Status Quo

2.4 Supply & Demand

2.5 Competition Pattern

2.6 Outlook

2.7 Sales Channel

3. Human Vaccine Market Segments in China

3.1 Hepatitis B Vaccine

3.2 Meningococcal Vaccine

3.3 Hepatitis A Vaccine

3.4 Influenza Vaccine

3.5 Hib Vaccine

3.6 Human Rabies Vaccine

3.7 Varicella Vaccine

3.8 Pneumococcal Vaccine

3.9 DPT Vaccine

3.10 Poliomyelitis Vaccine

4. Human Vaccine Import and Export in China

4.1 Export

4.2 Import

5. Major Human Vaccine Producers in China

Companies Mentioned

- Beijing Tiantan Biological Products

- Changchun BCHT Biotechnology

- Changchun Changsheng Life Sciences Limited

- China National Biotec Group

- Chongqing Zhifei Biological Products

- Dalian Hissen Bio-Pharm

- Hualan Biological Engineering

- Liaoning Chengda

- Shenzhen Kangtai Biological Products

- Sinovac Biotech

- Yunnan Walvax Biotechnology

- Zhejiang Tianyuan Bio-Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/jl9tz5/china_human

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact:
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Rates

View Comments (0)